Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 2/20 | 0.41 |
| ▸ | FFAR2 | O15552 | 6/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | PDE5A | O76074 | 1/20 | 0.37 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20835476 | 0.88 | FFAR2 (0.45) | RIPK1FFAR2HCRTR2 | |
| SCHEMBL20835627 | 0.87 | FFAR2 (0.38) | FFAR2MAOBMAOAOPRK1ALDH1A1 | |
| SCHEMBL20835408 | 0.87 | FFAR2 (0.45) | RIPK1FFAR2 | |
| SCHEMBL20835613 | 0.86 | FFAR2 (0.50) | RIPK1FFAR2MAOBMAOAPDE5A | |
| SCHEMBL21094369 | 0.86 | RIPK1 (0.45) | RIPK1FFAR2MAOBMAOAPDE5A | |
| SCHEMBL20835914 | 0.83 | FFAR2 (0.40) | RIPK1FFAR2 | |
| SCHEMBL20835618 | 0.82 | FFAR2 (0.41) | FFAR2 | |
| SCHEMBL20835556 | 0.82 | RIPK1 (0.47) | RIPK1FFAR2MAOBMAOAPDE5A | |
| SCHEMBL20835754 | 0.81 | RIPK1 (0.39) | RIPK1MAOBMAOAOPRK1ALDH1A1 | |
| SCHEMBL20835548 | 0.80 | RIPK1 (0.45) | RIPK1FFAR2MAOBMAOAPDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10995084-B2 | Pyrrolidine derivative | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2021-05-04 | — | — | US | disclosed |
| US-20200299273-A1 | PYRROLIDINE DERIVATIVE | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2020-09-24 | — | — | US | disclosed |
| EP-3459941-A1 | PYRROLIDINE DERIVATIVE | Kissei Pharmaceutical Co., Ltd. (JP) | 2019-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299273-A1 | PYRROLIDINE DERIVATIVE | CALCRL, NPY1R, GRPR | RIPK1 1917/4885FFAR2 634/4885MAOB 1506/4885 |
| US-10995084-B2 | Pyrrolidine derivative | CALCRL, NPY1R, GRPR | RIPK1 1917/4885FFAR2 634/4885MAOB 1506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.